Association of Obesity and Skeletal Muscle with Postoperative Survival in Non-Small Cell Lung Cancer.

Radiology

From the Department of Radiology (J.H.L.) and Department of Thoracic and Cardiovascular Surgery (J.L., Y.J.J., S.Y.P., J.H.C., Y.S.C., J.K., Y.M.S., H.K.K.), Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea; Department of Clinical Research Design and Evaluation, SAIHS

Published: January 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background A comprehensive assessment of skeletal muscle health is crucial to understanding the association between improved clinical outcomes and obesity as defined by body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) in lung cancer, but limited studies have been conducted on this topic. Purpose To investigate the association between BMI-defined obesity and survival in patients with non-small cell lung cancer who underwent curative resection, with a specific focus on the status of skeletal muscle assessed at CT. Materials and Methods This retrospective study investigated Korean patients with non-small cell lung cancer who underwent curative resection between January 2008 and December 2019. Patients were classified into nonobese (BMI <25) or obese (BMI ≥25) groups. Skeletal muscle status was assessed at CT at the level of the third lumbar vertebrae. Low skeletal muscle mass (LSMM) was defined as the sex-specific lowest quartile. Cox regression analysis was used to evaluate the associations of BMI and muscle status with overall survival. Results A total of 7076 patients (mean age, 62.5 years ± 9.7 [SD]; 4081 male) were included, of whom 2512 (35.5%) had a BMI greater than or equal to 25 (obese group). In the setting of absent LSMM and myosteatosis, patients in the obese group had longer overall survival compared with patients in the nonobese group (hazard ratio [HR], 0.77; 95% CI: 0.66, 0.90; = .001). The associations between obesity and lower mortality were observed only in male patients (HR, 0.72; 95% CI: 0.60, 0.85; < .001) and patients who had ever smoked (HR, 0.71; 95% CI: 0.60, 0.85; < .001) who were without LSMM and myosteatosis, with effect differing according to sex and smoking status ( value range, <.001 to .02 for interaction). Conclusion Obesity is associated with improved overall survival in patients with non-small cell lung cancer after curative resection when skeletal muscle mass and radiodensity are preserved. © RSNA, 2025 See also the editorial by Vannier in this issue.

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.241507DOI Listing

Publication Analysis

Top Keywords

lung cancer
16
skeletal muscle
12
non-small cell
12
cell lung
12
patients non-small
8
cancer underwent
8
underwent curative
8
curative resection
8
association obesity
4
obesity skeletal
4

Similar Publications

Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.

View Article and Find Full Text PDF

Reply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer.

JCO Precis Oncol

September 2025

Monica F. Chen, MD, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Gomez, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, and Helena A. Yu, MD, Division of Solid Tumor Oncology, Depart

View Article and Find Full Text PDF

Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS).

View Article and Find Full Text PDF